The Wegovy golden dose chart: what the titration schedule actually means

Step 1: why the schedule starts so low (0.25 mg and 0.5 mg)

The first pen you use contains 0.25 mg of semaglutide, four weekly doses at that strength. Its job is purely to let your digestive system adjust. At this level most people notice very little in the way of appetite change; nausea and other gut-related effects are generally mild because the dose is deliberately conservative. After four weeks the prescriber moves you to 0.5 mg, which begins to produce a more meaningful effect on appetite signals in the brain.

A question our prescribers hear regularly: "Can I skip the starter dose if I feel fine?" The honest answer is that feeling fine is partly the point, the slow start is what keeps you feeling fine. Rushing the schedule tends to produce the nausea and vomiting that make people want to stop altogether. The full breakdown of what each Wegovy strength does explains this in more detail.

Practically speaking, if you order by midday on a weekday the pen arrives the next working day via tracked DPD, which means you can plan your injection day around a routine that works, many people pick a fixed day so it becomes as automatic as any other weekly habit. The clinical review happens on the same day you complete your consultation, carried out by a real prescriber, not a system.

Step 2: the middle doses (1.0 mg and 1.7 mg) and where the "golden dose" idea comes from

Weeks nine to sixteen (approximately) cover the 1.0 mg and 1.7 mg strengths. This is where many people report a meaningful shift: appetite suppression becomes consistent, food noise quietens noticeably, and the GI side effects that peaked at earlier increases tend to settle within the first week or two of each new strength.

The term "golden dose" circulates online to describe the strength where this balance feels most comfortable, enough effect, manageable side effects. In the STEP 1 trial, published in the New England Journal of Medicine, participants on 2.4 mg semaglutide achieved an average weight reduction of around 15% over 68 weeks. The data doesn't define a single universally golden point; what it shows is that effect accumulates across the schedule. For some individuals 1.7 mg genuinely is a comfortable long-term dose; others find 2.4 mg better tolerated than they expected.

The Wegovy golden dose page goes into the concept in more depth if you want to explore what the evidence actually says versus the social-media version of the idea.

Step 3: reaching and staying at 2.4 mg (and the 7.2 mg option)

The standard maintenance dose is 2.4 mg, reached at around week seventeen. Most people stay here for the duration of treatment. In April 2026 the MHRA approved a dedicated single-dose 7.2 mg pen (three times the previous maximum) for adults with a BMI of 30 or above, following trial data showing around 20.7% average weight loss over 72 weeks at that strength. The MHRA's announcement confirmed the pen auto-doses, has a built-in covered needle and locks after use. Reaching 7.2 mg still requires titrating from 0.25 mg in the same stepwise way; a prescriber decides whether that ceiling is appropriate for you.

NICE recommends semaglutide for weight management only within a specialist service and for a maximum of two years, for adults meeting the relevant BMI and comorbidity thresholds. Private treatment through a regulated pharmacy follows the licensed criteria rather than the NHS access pathway, though the clinical review is no less thorough. If you want to understand what the cost picture looks like at each stage, the Wegovy prices page sets out what a legitimate private prescription typically includes.

The guidance on how to use the golden dose concept covers what to do if you feel you've found your optimal strength and want to discuss staying there rather than increasing further.

When the chart doesn't match your experience

The titration schedule is a framework, not a rigid timetable. Some people need to hold a dose for longer than four weeks because side effects haven't settled; others move through the early steps without difficulty but hit a plateau at 1.7 mg where the prescriber needs to reassess. The chart tells you the shape of the journey; it doesn't predict your specific path through it.

Common side effects across the schedule are GI-led: nausea, loose stools, constipation, reflux and fatigue tend to peak in the first week after each increase, then ease. The NHS semaglutide page lists these clearly and explains which ones warrant contacting a clinician. Severe, persistent stomach pain that radiates to the back should always be assessed urgently, the MHRA flagged acute pancreatitis as an infrequent but serious GI risk for GLP-1 medicines in early 2026.

If you're already on treatment elsewhere and want to transfer, or if you're considering starting, whether a golden dose exists for you personally is the kind of question worth raising at consultation. The prescribers at nume review every case individually, there's no algorithm deciding your next step.

When you're ready to see whether Wegovy is clinically suitable for you, check your eligibility with a free consultation.